Evofem Biosciences, Inc. (EVFM) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you. Good afternoon, everyone, and welcome to the FOSM Biosciences Q1 2022 results call. If you haven't done so already, I encourage you to access the presentation that accompanies this call and the press release to be issued at market close, both of which may be found at FOSM.com under the Investors tab. Before we begin, I would like to remind you that remarks on this call will contain four of those statements, which are made only as of today, May 4th, 2022. For more detailed description of important risk factors that could cause our actual results to differ materially, please refer to our annual report on Form 10-A and our most recently filed statute. With that, I'll turn the call over to Evo Femm's CEO, Sandra Pelletier. Thank you, Amy, and thanks to everyone for joining us today. I am proud that today we are reporting our third consecutive quarter of improved operating results. We significantly improved growth to net. We increased FEXE net product sales, we reduced our total operating expenses, and we improved our long-term operations. This testifies to our ongoing disciplined approach to fiscal improvement. On the call today, I'm going to provide color on the trends and initiatives that we believe will drive further revenue growth and enable us to achieve our stated guidance and build long-term value for shareholders and the women and prescribers who rely on FECSI for hormone-free contraception. The most important development is that last week we received confirmation from one of the largest PBMs in the nation that they will add FECSI to their national template formulary with no restrictions. First, though, I'll ask our CFO, Jay Files, to review the financial results. Jay? Thank you, Sandra. Today I'm going to focus on the first quarter of 2022 results rel...